Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Free Cash Flow came in at -$46.3 million in Q1 2026, up 8.0% YoY from -$42.9 million in Q1 2025, and up 2.82% on a QoQ basis from -$47.7 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Free Cash Flow data on file, last reported at -$46.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 8.0% year-over-year to -$46.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.7 million (up 48.09% YoY) and the FY2025 annual result came in at -$178.7 million, up 53.23% from the prior year.
- Free Cash Flow rose to -$46.3 million in Q1 2026, from -$47.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$17.7 million in Q1 2022 to a low of -$146.8 million in Q4 2022.
- A 5-year average of -$73.4 million and a median of -$78.5 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 74.76% — and 2023, when it tumbled 522.11%.
- Tracing DNA's Free Cash Flow over 5 years: stood at -$146.8 million in 2022, then soared by 34.67% to -$95.9 million in 2023, then declined by 9.26% to -$104.8 million in 2024, then soared by 54.49% to -$47.7 million in 2025, then rose by 2.82% to -$46.3 million in 2026.
- The last three Free Cash Flow figures came in at -$46.3 million (Q1 2026), -$47.7 million (Q4 2025), and -$39.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -46.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.89 Mn |
| Jun 30, 2026 | -46.89 Mn |
| Mar 31, 2026 | -46.34 Mn |
| Mar 31, 2026 | -46.34 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Sep 30, 2025 | -39.14 Mn |
| Sep 30, 2025 | -39.14 Mn |
| Jun 30, 2025 | -41.53 Mn |
| Jun 30, 2025 | -41.53 Mn |
| Mar 31, 2025 | -50.37 Mn |
| Mar 31, 2025 | -50.37 Mn |
| Dec 31, 2024 | -104.78 Mn |
| Dec 31, 2024 | -104.78 Mn |
| Sep 30, 2024 | -102.86 Mn |
| Sep 30, 2024 | -102.86 Mn |
| Jun 30, 2024 | -78.51 Mn |
| Jun 30, 2024 | -78.51 Mn |
| Mar 31, 2024 | -95.97 Mn |
| Mar 31, 2024 | -95.97 Mn |